Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 15/20 | 0.65 |
| ▸ | AVPR2 | P30518 | 8/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.65 |
| ▸ | OXTR | P30559 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4994870 | 0.91 | AVPR1A (0.66) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL5007135 | 0.87 | AVPR1A (0.71) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL5000787 | 0.86 | AVPR1A (0.62) | AVPR1AAVPR2KCNH2 | |
| SCHEMBL2511034 | 0.85 | AVPR1A (0.71) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL2512963 | 0.85 | AVPR1A (0.71) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL16104226 | 0.85 | AVPR1A (0.71) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL5000983 | 0.85 | AVPR1A (0.65) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL5007116 | 0.79 | AVPR1A (0.61) | AVPR1AAVPR2KCNH2 | |
| SCHEMBL5101520 | 0.79 | AVPR1A (1.00) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL5098210 | 0.79 | AVPR1A (0.83) | AVPR1AAVPR2KCNH2OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456170-B2 | Triazolobenzodiazepines and their use as vasopressin antagonists | PFIZER INC. (US) | 2008-11-25 | — | — | US | claimed |
| US-7456170-B2 | Triazolobenzodiazepines and their use as vasopressin antagonists | PFIZER INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456170-B2 | Triazolobenzodiazepines and their use as vasopressin antagonists | PFIZER INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456170-B2 | Triazolobenzodiazepines and their use as vasopressin antagonists | PFIZER INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070249585-A1 | Triazolobenzodiazepines and Their Use as Vasopressin Antagonists | PFIZER INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249585-A1 | Triazolobenzodiazepines and Their Use as Vasopressin Antagonists | PFIZER INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249585-A1 | Triazolobenzodiazepines and Their Use as Vasopressin Antagonists | PFIZER INC. | 2007-10-25 | — | — | US | disclosed |
| EP-1784408-A1 | TRIAZOLOBENZODIAZEPINES AND THEIR USE AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021882-A1 | TRIAZOLOBENZODIAZEPINES AND THEIR USE AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021882-A1 | TRIAZOLOBENZODIAZEPINES AND THEIR USE AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249585-A1 | Triazolobenzodiazepines and Their Use as Vasopressin Antagonists | AVPR2, AVPR1A, AVPR1B | AVPR1A 2/4885AVPR2 1/4885KCNH2 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.